Lead Product(s): IBI362
Therapeutic Area: Nutrition and Weight Loss Product Name: LY3305677
Highest Development Status: Phase II Product Type: Peptide
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2021
IBI362, a glucagon-like peptide 1 receptor (GLP-1R) and glucagon receptor (GCGR) dual agonist used to assess the efficacy and safety of IBI362 in overweight or obese subjects in China.